Physician profile
Gail Bodner
NPI 1720139090
$4,081.34
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $538 · 2021: $923 · 2022: $565 · 2023: $762 · 2024: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,665.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $780.85 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $674.28 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $539.11 | 2021-2024 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $415.83 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Amarin Pharma, INC. | $402.00 | 2019-2021 | |
| Glaxosmithkline, LLC. | $288.20 | 2019-2024 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $175.70 | 2019-2021 | |
| Pfizer INC. | $129.02 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $98.12 | 2019-2023 | Vaxneuvance, Gardasil 9 |
| Biohaven Pharmaceutical Holding Company LTD. | $72.49 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $55.39 | 2019 | |
| Phathom Pharmaceuticals, INC. | $48.03 | 2024 | Voquezna |
| Exact Sciences Corporation | $43.82 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.96 | 2019-2022 | |
| Astellas Pharma US INC | $37.88 | 2019-2024 | Veozah |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $37.07 | 2021 | |
| Biofire Diagnostics, LLC | $35.97 | 2020 | |
| Corcept Therapeutics | $28.57 | 2024 | Korlym |
| Otsuka America Pharmaceutical, INC. | $26.88 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $21.61 | 2019 | |
| Mylan Specialty L.P. | $21.34 | 2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $18.90 | 2023 | |
| Sanofi-Aventis U.S. LLC | $18.10 | 2022 | |
| Allergan, INC. | $15.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.75 | 2021 | |
| Dexcom, INC. | $13.91 | 2024 | Dexcom G6 Transmitter |
| Amgen INC. | $13.21 | 2019 | |
| Organon LLC | $13.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gail Bodner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.